美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MRNA期權收益策略ETF-YieldMax

19.39

-0.2219-1.13%

成交量：7.57萬

成交額：148.73萬

市值：9,510.74萬

市盈率：- -

高：19.94

開：19.56

低：19.34

收：19.61

52周最高：37.05

52周最低：13.60

股本：490.50萬

流通股本：480.50萬

量比：2.59

換手率：1.58%

股息：18.59

股息率：95.86%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

疫苗交易強勁，諾維信上調 2026 年調整後收入展望

美國 FDA 局長馬卡里説，FDA 支持 mRNA 疫苗，但美國納税人不應承擔費用

旗艦企業 Generate Biomedicines 希望在美國 IPO 中獲得 22 億美元估值

美國研究綜述-Akamai Technologies、Albemarle、Nordson

美國研究綜述-Akamai Technologies、Albemarle、Nordson

Piper Sandler上調莫德納目標價至69美元

BioNTech控告Moderna侵犯新冠疫苗專利

环球市场播报

異動解讀 | FDA立場轉變改善流感疫苗監管前景，Moderna盤中大漲5.06%

異動解讀 | FDA同意審查流感疫苗，Moderna盤前大漲5.28%

Moderna(MRNA.US)：美國食品藥品監督管理局將啓動對其在研季節性流感疫苗申報的審查。

異動解讀 | Moderna盤中大漲7.97%，四季度營收超預期及疫苗進展提振信心

Moderna高管透露：公司期待年內獲歐洲批准流感與新冠聯合疫苗

Moderna四季度營收6.78億美元好於預期，重申年度增速指引

老虎资讯综合

Moderna預期2026年營收分佈：美國與國際市場各佔半壁江山

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/MRNY/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MRNY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNY\",,,,,undefined,":{"symbol":"MRNY","market":"US","secType":"STK","nameCN":"MRNA期權收益策略ETF-YieldMax","latestPrice":19.39,"timestamp":1772119422548,"preClose":19.6119,"halted":0,"volume":75695,"delay":0,"changeRate":-0.011314559017739128,"floatShares":4804974,"shares":4904974,"eps":0,"marketStatus":"交易中","change":-0.2219,"latestTime":"02-26 10:24:16 EST","open":19.56,"high":19.94,"low":19.3401,"amount":1487280.9449099998,"amplitude":0.030589,"askPrice":19.44,"askSize":221,"bidPrice":19.33,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1772139600000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":19.6119,"sharesOutstanding":4904974,"nav":19.51,"aum":95696042.74,"dividendRate":0.958621,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":19.67,"preClose":19.6119,"latestTime":"09:24 EST","volume":3592,"amount":70539.717552,"timestamp":1772115840117,"change":0.0581,"changeRate":0.002962,"amplitude":0.017336},"postHourTrading":{"tag":"盘后","latestPrice":20.05,"preClose":19.99,"latestTime":"19:55 EST","volume":16871,"amount":339763.9125,"timestamp":1772067314830,"change":0.06,"changeRate":0.003002,"amplitude":0.02051},"volumeRatio":2.58903,"impliedVol":0.1425,"impliedVolPercentile":0.044},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNY\",,,,,undefined,":{"symbol":"MRNY","floatShares":4804974,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.58903,"shares":4904974,"dividePrice":18.587667,"high":19.94,"amplitude":0.030589,"preClose":19.6119,"low":19.3401,"week52Low":13.6,"pbRate":"--","week52High":37.05,"institutionHeld":0,"latestPrice":19.39,"committee":-0.049881,"eps":0,"divideRate":0.958621,"volume":75695,"delay":0,"ttmEps":0,"open":19.56,"prevYearClose":14.7,"prevWeekClose":19.53,"prevMonthClose":18.9,"prevQuarterClose":14.7,"fiveDayClose":19.56,"twentyDayClose":19.85,"sixtyDayClose":15.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MRNY\",params:#limit:5,,,undefined,":[{"date":"2026-02-26","symbol":"MRNY","amount":0.3781,"announcedDate":"2026-02-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-26","defaultRemindTime":1772116200000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-27","payableDate":"2026-02-26","currency":"USD","dateTimestamp":1772082000000,"payDate":"2026-02-27"},{"date":"2026-02-19","symbol":"MRNY","amount":0.3174,"announcedDate":"2026-02-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-19","defaultRemindTime":1771511400000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-20","payableDate":"2026-02-19","currency":"USD","dateTimestamp":1771477200000,"payDate":"2026-02-20"},{"date":"2026-02-12","symbol":"MRNY","amount":0.3473,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-12","defaultRemindTime":1770906600000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-13","payableDate":"2026-02-12","currency":"USD","dateTimestamp":1770872400000,"payDate":"2026-02-13"},{"date":"2026-02-05","symbol":"MRNY","amount":0.2662,"announcedDate":"2026-02-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-05","defaultRemindTime":1770301800000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-06","payableDate":"2026-02-05","currency":"USD","dateTimestamp":1770267600000,"payDate":"2026-02-06"},{"date":"2026-01-29","symbol":"MRNY","amount":0.4791,"announcedDate":"2026-01-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-29","defaultRemindTime":1769697000000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-30","payableDate":"2026-01-29","currency":"USD","dateTimestamp":1769662800000,"payDate":"2026-01-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MRNY\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-07","recordDate":"2023-12-08","paymentDate":"2023-12-13","value":0.413,"currency":"USD"},{"executeDate":"2024-01-05","recordDate":"2024-01-08","paymentDate":"2024-01-09","value":2.6542,"currency":"USD"},{"executeDate":"2024-02-07","recordDate":"2024-02-08","paymentDate":"2024-02-09","value":0.5944,"currency":"USD"},{"executeDate":"2024-03-06","recordDate":"2024-03-07","paymentDate":"2024-03-08","value":1.131,"currency":"USD"},{"executeDate":"2024-04-04","recordDate":"2024-04-05","paymentDate":"2024-04-08","value":0.7832,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MRNY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MRNY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614404439","title":"疫苗交易強勁，諾維信上調 2026 年調整後收入展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2614404439","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614404439?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 21:00","pubTimestamp":1772110852,"startTime":"0","endTime":"0","summary":"疫苗交易强劲，诺维信上调 2026 年调整后收入展望Mariam Sunny/Michael Erman. 路透2月26日 - 诺维信 NVAX.O周四上调了2026年的调整后收入预期，因为该公司预计疫苗供应和许可交易的里程碑付款将抵消需求下降带来的压力。这家生物技术公司目前预计 2026 年调整后的收入为 2.3 亿至 2.7 亿美元，高于之前预测的 1.85 亿至 2.05 亿美元。根据 LSEG 编制的数据，诺维信第四季度收入增长 67%，达到 1.47 亿美元，高于分析师平均预期的 7,884 万美元。该季度净收入为 1,800 万美元，而去年同期净亏损为 8,100 万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL4S3ZM19S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999011175.SGD","LU1066053197.SGD","SG9999003800.SGD","LU1023059063.AUD","LU0306806265.USD","BK4551","IE0002270589.USD","SG9999002224.SGD","LU1883839398.USD","BK4532","LU0321505868.SGD","IE000M9KFDE8.USD","MRNY","LU0170899867.USD","IE00BBT3K403.USD","IE00BLSP4452.SGD","IE00B19Z3581.USD","MRNX","NVAX","SG9999001176.SGD","BK4599","BK4501","LU0985481810.HKD","LU0289739699.SGD","SG9999013999.USD","BK4568","LU0456855351.SGD","LU0868494617.USD","BK4592","BK4550","IE00B19Z3B42.SGD","BK4534","LU1894683264.USD","LU0225284248.USD","BK4547","LU0234572021.USD","LU1057294990.SGD","SG9999001176.USD","SGXZ57979304.SGD","BK4139","LU0225771236.USD","SG9999002232.USD","IE00BLSP4239.USD","LU0321505439.SGD","LU1066051498.USD","BK4581","BK4007","BK4585","BK4588","LU1894683348.USD","LU0306807586.USD","LU0058720904.USD","BK4533","LU0122379950.USD","BK4548"],"gpt_icon":0},{"id":"2613873230","title":"美國 FDA 局長馬卡里説，FDA 支持 mRNA 疫苗，但美國納税人不應承擔費用","url":"https://stock-news.laohu8.com/highlight/detail?id=2613873230","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613873230?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 04:11","pubTimestamp":1771877495,"startTime":"0","endTime":"0","summary":"美国 FDA 局长马卡里说，FDA 支持 mRNA 疫苗，但美国纳税人不应承担费用马卡里说，FDA 支持 mRNA 疫苗，但不支持纳税人的资助马卡里为 HHS 削减 mRNA 经费的决定辩护马卡里认为，公司有能力负担 mRNA 研究费用Ahmed Aboulenein. 在我任职之初，我们已经批准了两种 mRNA 疫苗。马卡里称美国因资金问题拒绝资助MRNA马卡里为美国卫生与公众服务部 8 月份决定  停止其生物医学研究部门的 mRNA 疫苗开发活动辩护。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4S3ZJ1JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4007","IE00BBT3K403.USD","LU0234572021.USD","LU0432979614.USD","LU0985481810.HKD","LU1983299246.USD","LU1037948897.HKD","SG9999003800.SGD","LU0266013472.USD","LU1571399168.USD","BK4592","IE00BN8TJ469.HKD","LU1989772840.SGD","LU1116320901.HKD","LU1023059063.AUD","LU1093756168.USD","LU1894683264.USD","BK4559","LU0965509010.AUD","LU1035773651.USD","IE00B19Z3581.USD","LU2089984988.USD","BK4550","LU0225284248.USD","BK4585","LU1291159041.SGD","LU1941712348.USD","LU0106261372.USD","LU1934455194.USD","IE00B4R5TH58.HKD","LU0648001328.SGD","BK4534","LU2361044865.SGD","IE0002270589.USD","LU2361044949.HKD","LU1934455863.HKD","IE0002141913.USD","LU0170899867.USD","BK4533","LU0211331839.USD","LU1093756325.SGD","LU1162221912.USD","SG9999014575.USD","LU0265550946.USD","LU0130517989.USD","LU1941712264.USD","LU2361045086.USD","LU1917777945.USD","LU1066051498.USD","LU2023250843.SGD","LU0965508806.USD","LU2112291526.USD","SG9999002224.SGD","LU0868494617.USD","LU1989771016.USD","LU0320765646.SGD","IE00B1BXHZ80.USD","LU1057294990.SGD","SGXZ57979304.SGD","LU1699723380.USD","SG9999002232.USD","IE000M9KFDE8.USD","BK4568","LU1037948541.HKD","LU1934455277.USD","BK4532","SG9999015341.SGD","LU1066051225.USD","LU1430594728.SGD","MRNX","LU1989772923.USD","SG9999001176.SGD","LU0321505439.SGD","LU1894683348.USD","BK4599","IE0009355771.USD","LU0006306889.USD","IE00BJJMRZ35.SGD","BK4581","LU0320765489.SGD","SG9999015358.SGD","LU1585245621.USD","LU0265550359.USD","IE00BJT1NW94.SGD","IE00BLSP4452.SGD","BK4139","LU0225771236.USD","BK4501","LU0122379950.USD","BK4548","LU0098860793.USD","LU2125154778.USD","LU1929549753.HKD","LU1066051811.HKD","LU0203347892.USD","LU0965509283.SGD","LU2468319806.SGD","SG9999013999.USD","LU2360032135.SGD","SG9999001440.SGD","LU2461242641.AUD","MRK","LU0306806265.USD","SG9999001176.USD","LU0321505868.SGD","LU0477156953.USD","LU0456855351.SGD","LU0861579265.USD","LU1974910355.USD","BK4516","LU1069347547.HKD","LU0289739699.SGD","IE00B2B36J28.USD","BK4588","LU1116320737.USD","SG9999014567.USD","LU0238689110.USD","LU0980610538.SGD","LU0965509101.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","LU0130102774.USD","SG9999014559.SGD","MRNY","IE00BSNM7G36.USD","LU2023250504.SGD","LU0058720904.USD","LU1883839398.USD","LU0208291251.USD","LU1066053197.SGD","LU1201861249.SGD","IE00B19Z3B42.SGD","LU2125154935.USD","SG9999014542.SGD","MRNA","LU2324357040.USD","LU1061106388.HKD","LU0306807586.USD","LU0985320562.USD","LU0203345920.USD","LU2106854487.HKD","IE00BLSP4239.USD","SG9999011175.SGD"],"gpt_icon":1},{"id":"2613789435","title":"旗艦企業 Generate Biomedicines 希望在美國 IPO 中獲得 22 億美元估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2613789435","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613789435?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 19:54","pubTimestamp":1771847674,"startTime":"0","endTime":"0","summary":"更新版 3-旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值在第 3、6、7 段添加分析师评论Arasu Kannagi Basil路透2月23日 - 药物开发商Generate Biomedicines周一表示，该公司在美国首次公开募股的目标估值将高达21.7亿美元，从而进入上市步伐加快的生物技术市场。Aktis Oncology AKTS.O、Agomab Therapeutics AGMB.O、Veradermics MANE.N、Eikon Therapeutics EIKN.O和SpyGlass Pharma SGP.O今年已经登陆美国资本市场。\"Generate公司用于治疗严重哮喘的主要候选产品GB-0895正在进行后期试验。预计这项研究将于 2028 年上半年全部完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4S3ZJ0Q2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836757.USD","LU2028103732.USD","AMGN","BK4139","LU2750360997.AUD","LU0234570918.USD","LU2471134796.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU0096364046.USD","BK4550","LU1162221912.USD","BK4566","LU1868836914.USD","MRNA","SGP","BK4532","LU0889565916.HKD","LU2265009873.SGD","BK4552","IE0009355771.USD","LU1244550494.USD","LU0122379950.USD","LU0795875169.SGD","LU2133065610.SGD","EIKN","LU0251142724.SGD","LU1791807156.HKD","IE0004091025.USD","BK4127","LU2089283258.USD","LU0098860793.USD","LU0912757837.SGD","LU2111349929.HKD","LU2237443465.HKD","MRNY","MRNX","BK4534","MANE","LU2750360641.GBP","LU0106261372.USD","PIPR","BK4516","IE00BKVL7J92.USD","AGMB","AKTS","LU1804176565.USD","LU2237443622.USD","GSX"],"gpt_icon":0},{"id":"2613920292","title":"美國研究綜述-Akamai Technologies、Albemarle、Nordson","url":"https://stock-news.laohu8.com/highlight/detail?id=2613920292","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613920292?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 15:27","pubTimestamp":1771831664,"startTime":"0","endTime":"0","summary":"美国研究综述-Akamai Technologies、Albemarle、Nordson路透2月23日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，包括Akamai Technologies、Albemarle和Nordson。股票条目按字母顺序排列。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4S3ZJ0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","DE","RNG","LU2168563687.JPY","FIX","LU2125154778.USD","ALBG","OBDC","DKNG","LU2237443622.USD","DRAY","EPAM","LU2210149790.SGD","AKAM","LU1621768115.EUR","MRNX","CPRT","OWL","LU0957791311.USD","AGM","NDSN","BKNG","LOW","DASX","LU2471134879.HKD","LU0994945656.USD","EXR","BKNU","CCOI","HRZN","YSS","CVNX","DKNX","NEE","DKUP","MRNY","JXN","LU0240877869.USD","OTF","CVNY","ALB","TTAN","LU0114720955.EUR","CAR","LIFE","LU0882574055.USD"],"gpt_icon":1},{"id":"2613202921","title":"美國研究綜述-Akamai Technologies、Albemarle、Nordson","url":"https://stock-news.laohu8.com/highlight/detail?id=2613202921","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613202921?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 15:27","pubTimestamp":1771831664,"startTime":"0","endTime":"0","summary":"美国研究综述-Akamai Technologies、Albemarle、Nordson路透2月23日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，包括Akamai Technologies、Albemarle和Nordson。股票条目按字母顺序排列。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4T3ZJ0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989763690.USD","BKNG","LU1043141396.HKD","NDSN","RNG","OWL","LIFE","YSS","OTF","ALB","HRZN","FIX","IE00BD6J9T35.USD","OBDC","DKUP","DKNG","BKNU","DRAY","DKNX","LOW","LU2237443895.HKD","LU1366333091.USD","LU2045819591.USD","CPRT","DASX","MRNY","DE","CVNX","EPAM","JXN","TTAN","LU0472753341.HKD","MRNX","BMY","AGM","EXR","CAR","CCOI","ALBG","AKAM","NEE","BK4597","LU1989771016.USD","LU2298322129.HKD","CVNY","LU0130517989.USD"],"gpt_icon":1},{"id":"2613730353","title":"Piper Sandler上調莫德納目標價至69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613730353","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613730353?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 14:40","pubTimestamp":1771828834,"startTime":"0","endTime":"0","summary":"格隆汇2月23日｜Piper Sandler将莫德纳目标价从63美元上调至69美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223144112a7151e48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223144112a7151e48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","MRNY","BK4568","BK4548","BK4139","BK4551","BK4533","MRNA","BK4532","BK4534","MRNX","BK4501","BK4588"],"gpt_icon":0},{"id":"2612287922","title":"BioNTech控告Moderna侵犯新冠疫苗專利","url":"https://stock-news.laohu8.com/highlight/detail?id=2612287922","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612287922?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 03:26","pubTimestamp":1771529160,"startTime":"0","endTime":"0","summary":"德国生物制药公司BioNTech周四在特拉华州联邦法院起诉Moderna，指控Moderna的新冠疫苗 mNEXSPIKE侵犯了BioNTech和辉瑞公司的竞争性疫苗Comirnaty的相关专利。　　该诉讼称，Moderna公司于2025年获得美国食品药品管理局批准的下一代新冠疫苗mNEXSPIKE，侵犯了BioNTech公司在用于简化mRNA疫苗设计的技术方面的权利，该技术允许以较低剂量为患者接种。　　Moderna在2022年起诉BioNTech及其合作伙伴辉瑞公司侵犯了Comirnaty的专利权，目前诉讼仍在进行中。","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-20/doc-inhnkyhw6558658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MRNY","MRNX","MRNA","BNTX"],"gpt_icon":1},{"id":"1102127485","title":"異動解讀 | FDA立場轉變改善流感疫苗監管前景，Moderna盤中大漲5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102127485","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102127485?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 02:59","pubTimestamp":1771527578,"startTime":"0","endTime":"0","summary":"Moderna, Inc.  今日盘中股价大幅上涨5.06%，引起了市场的广泛关注。消息面上，美国食品和药物管理局改变了方针，将审查Moderna新型流感疫苗mRNA-1010的修订申请。此前一周，FDA曾拒绝了该疫苗的申请，引发了市场担忧，而此次立场的迅速反转显著改善了该疫苗的监管前景。多家券商随即更新了观点，其中William Blair将Moderna流感疫苗获得监管成功的概率从10%大幅提高到55%。RBC Capital Markets认为，FDA的迅速反转符合当前政策模式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","MRNA","MRNY"],"gpt_icon":0},{"id":"1179667827","title":"異動解讀 | FDA同意審查流感疫苗，Moderna盤前大漲5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179667827","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179667827?lang=zh_tw&edition=fundamental","pubTime":"2026-02-18 20:39","pubTimestamp":1771418340,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA) 今日盘前股价大幅上涨5.28%，引起了市场的广泛关注。消息面上，美国食品和药物管理局（FDA）已同意对Moderna公司的季节性流感疫苗mRNA-1010进行审查。此前，FDA曾以试验设计存在缺陷为由拒绝了审查申请，而此次公司提交了修改后的方案，寻求全面批准该疫苗用于50至64岁人群，并加速批准用于65岁及以上人群，同时承诺在上市后进行额外的研究。这一监管进展被视为公司产品管线推进的重要一步。如果获得批准，该疫苗最早可能在2026/27年流感季节上市，为Moderna带来新的增长动力。欧洲、加拿大和澳大利亚的监管机构也在同步审查该候选疫苗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","MRNX","MRNY"],"gpt_icon":0},{"id":"2612946448","title":"Moderna(MRNA.US)：美國食品藥品監督管理局將啓動對其在研季節性流感疫苗申報的審查。","url":"https://stock-news.laohu8.com/highlight/detail?id=2612946448","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612946448?lang=zh_tw&edition=fundamental","pubTime":"2026-02-18 20:04","pubTimestamp":1771416243,"startTime":"0","endTime":"0","summary":"","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MRNY","BK4533","BK4548","BK4585","MRNA","MRNX","BK4588","BK4139","BK4568","BK4532","BK4551","BK4501","BK4534"],"gpt_icon":0},{"id":"1167501095","title":"異動解讀 | Moderna盤中大漲7.97%，四季度營收超預期及疫苗進展提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1167501095","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167501095?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 22:48","pubTimestamp":1770994100,"startTime":"0","endTime":"0","summary":"Moderna, Inc.  今日盘中股价大幅上涨7.97%，引起了市场的广泛关注。消息面上，Moderna公布的2025年第四季度财务业绩表现强劲，营收达到6.78亿美元，超出了市场分析师平均预期的6.261亿美元，这主要得益于其新冠疫苗在美国的销售好于预期。同时，公司重申了2026年营收同比增长10%的业绩指引，并预期美国市场与国际市场将各贡献约50%的营收，展现了均衡的全球化布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","MRNY","MRNX"],"gpt_icon":0},{"id":"1136221151","title":"Moderna高管透露：公司期待年內獲歐洲批准流感與新冠聯合疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1136221151","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136221151?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 21:38","pubTimestamp":1770989892,"startTime":"0","endTime":"0","summary":"Moderna公司高管在电话会议中表示，公司正积极争取其流感与新冠联合疫苗在今年内获得欧洲监管机构的批准。\n这一表态凸显了Moderna在推进组合疫苗商业化进程中的关键步伐，若顺利获批，将有望为欧洲地区提供更高效的呼吸道疾病防护方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4534","BK4548","MRNY","BK4532","MRNX","BK4551","BK4533","MRNA","BK4585","BK4501","BK4568","BK4588"],"gpt_icon":0},{"id":"1142377976","title":"Moderna四季度營收6.78億美元好於預期，重申年度增速指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1142377976","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142377976?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 20:17","pubTimestamp":1770985052,"startTime":"0","endTime":"0","summary":"公司正在开发更新的产品。","market":"us","thumbnail":"https://static.tigerbbs.com/2f3840dad459cd6d96e214702ddd10d3","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/2f3840dad459cd6d96e214702ddd10d3"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Moderna四季度营收6.78亿美元好于预期，重申年度增速指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","MRNX","MRNA"],"gpt_icon":0},{"id":"1149918830","title":"Moderna預期2026年營收分佈：美國與國際市場各佔半壁江山","url":"https://stock-news.laohu8.com/highlight/detail?id=1149918830","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149918830?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 20:03","pubTimestamp":1770984217,"startTime":"0","endTime":"0","summary":"Moderna公司最新预测显示，其2026年的全球营收结构将呈现均衡态势——预计美国本土市场与国际市场的贡献比例将分别达到约50%。这一战略展望凸显了该生物技术巨头在巩固北美业务的同时，正加速推进全球化布局的步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4568","MRNA","BK4532","BK4139","BK4533","BK4585","BK4551","BK4588","BK4501","MRNX","BK4534","BK4548"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}